These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 3014173)
1. Laboratory and epidemiologic evaluation of an enzyme immunoassay for antibodies to HTLV-III. Ward JW; Grindon AJ; Feorino PM; Schable C; Parvin M; Allen JR JAMA; 1986 Jul; 256(3):357-61. PubMed ID: 3014173 [TBL] [Abstract][Full Text] [Related]
2. Detection of acquired immunodeficiency syndrome (AIDS) retrovirus antibody by lymphadenopathy-associated virus (LAV) enzyme immunoassay in low- and high-risk populations. Ragni MV; Lewis JH; Bracken M; Toth R; Stokes J; Steffensen DO Transfusion; 1986; 26(3):299-301. PubMed ID: 3010516 [TBL] [Abstract][Full Text] [Related]
3. HTLV-III/LAV infection in hemodialysis patients. Peterman TA; Lang GR; Mikos NJ; Solomon SL; Schable CA; Feorino PM; Britz JA; Allen JR JAMA; 1986 May; 255(17):2324-6. PubMed ID: 3007792 [TBL] [Abstract][Full Text] [Related]
4. Performance evaluation of the Abbott HTLV III EIA, a test for antibody to HTLV III in donor blood. Barrett JE; Dawson G; Heller J; Bairstow C; Fico R; Webber JS; Gutierrez R; Decker RH Am J Clin Pathol; 1986 Aug; 86(2):180-5. PubMed ID: 3017089 [TBL] [Abstract][Full Text] [Related]
5. Limitations of enzyme immunoassay tests for detection of HTLV-III/LAV antibodies. Lyons SF; McGillivray GM; Coppin AP; Schoub BD S Afr Med J; 1985 Oct; 68(8):575-6. PubMed ID: 2996159 [TBL] [Abstract][Full Text] [Related]
6. Update: Public Health Service workshop on human T-lymphotropic virus type III antibody testing--United States. Centers for Disease Control (CDC) MMWR Morb Mortal Wkly Rep; 1985 Aug; 34(31):477-8. PubMed ID: 2991728 [TBL] [Abstract][Full Text] [Related]
7. Serologic and molecular typing of human T-lymphotropic virus among blood donors in Maputo City, Mozambique. Gudo ES; Abreu CM; Mussá T; Augusto Ado R; Otsuki K; Chambo E; Amade N; Tanuri A; Ferreira OC; Jani IV; Transfusion; 2009 Jun; 49(6):1146-50. PubMed ID: 19222818 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of a new confirmatory assay for antibodies against lymphadenopathy-associated virus (LAV)/human T-lymphotropic virus type III (HTLV III). Abb J Vox Sang; 1986; 51(3):233-5. PubMed ID: 3544497 [TBL] [Abstract][Full Text] [Related]
9. Assessment of screening as a preventive technology: the example of HTLV-III/LAV antibody testing. Ory HW; Koplan JP; Allen JR Isr J Med Sci; 1986; 22(7-8):524-8. PubMed ID: 3640749 [TBL] [Abstract][Full Text] [Related]
10. Importance of western blot analysis in predicting infectivity of anti-HTLV-III/LAV positive blood. Esteban JI; Shih JW; Tai CC; Bodner AJ; Kay JW; Alter HJ Lancet; 1985 Nov; 2(8464):1083-6. PubMed ID: 2865566 [TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus antibody screening in blood donors from India, Nigeria and Thailand. Kühnl P; Seidl S; Ray V; Kulkarni AG; Mba EC; Chandanayingyong D Vox Sang; 1987; 52(3):203-5. PubMed ID: 3300027 [TBL] [Abstract][Full Text] [Related]
12. Transfusion-associated acquired immunodeficiency syndrome. Evidence for persistent infection in blood donors. Feorino PM; Jaffe HW; Palmer E; Peterman TA; Francis DP; Kalyanaraman VS; Weinstein RA; Stoneburner RL; Alexander WJ; Raevsky C N Engl J Med; 1985 May; 312(20):1293-6. PubMed ID: 2985992 [TBL] [Abstract][Full Text] [Related]
13. HLA antibodies as a cause of false-positive reactions in screening enzyme immunoassays for antibodies to human T-lymphotropic virus type III. Sayers MH; Beatty PG; Hansen JA Transfusion; 1986; 26(1):113-5. PubMed ID: 3003973 [TBL] [Abstract][Full Text] [Related]
14. Long-term serological follow-up of blood donors with an HTLV-indeterminate western blot: antibody profile of seroconverters and individuals with false reactions. Martins ML; Santos AC; Namen-Lopes MS; Barbosa-Stancioli EF; Utsch DG; Carneiro-Proietti AB J Med Virol; 2010 Oct; 82(10):1746-53. PubMed ID: 20827773 [TBL] [Abstract][Full Text] [Related]
15. Detection of antibodies to human T-lymphotropic virus type 1 (HTLV-1). Fang CT; Williams AE; Sandler SG; Slamon DJ; Poiesz BJ Transfusion; 1988; 28(2):179-83. PubMed ID: 2832983 [TBL] [Abstract][Full Text] [Related]
16. Human T-lymphotropic virus type I/II infections in volunteer blood donors from Northern and Western Greece: increased prevalence in one blood bank unit. Zervou EK; Georgiadou S; Tzilianos M; Georgitsi P; Pournara V; Nousis S; Pappas C; Daskalou L; Vrettou A; Karabini F; Dalekos GN Eur J Intern Med; 2004 Nov; 15(7):422-427. PubMed ID: 15581745 [TBL] [Abstract][Full Text] [Related]
17. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. Rook AH; Lane HC; Folks T; McCoy S; Alter H; Fauci AS J Immunol; 1987 Feb; 138(4):1064-7. PubMed ID: 3027168 [TBL] [Abstract][Full Text] [Related]
18. Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications. Weiss SH; Goedert JJ; Sarngadharan MG; Bodner AJ; Gallo RC; Blattner WA JAMA; 1985 Jan; 253(2):221-5. PubMed ID: 2981369 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of HTLV-III/LAV antibody in selected populations in Thailand. Wangroongsarb Y; Weniger BG; Wasi C; Traisupa A; Kunasol P; Rojanapithayakorn W; Fucharoen S Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):517-20. PubMed ID: 3869739 [TBL] [Abstract][Full Text] [Related]
20. Human T-lymphotropic virus antibody screening of blood donors: rates of false-positive results and evaluation of a potential donor reentry algorithm. Stramer SL; Notari EP; Zou S; Krysztof DE; Brodsky JP; Tegtmeier GE; Dodd RY Transfusion; 2011 Apr; 51(4):692-701. PubMed ID: 20946198 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]